Stock ETNB 89BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News 89bio, Inc.

Equities

ETNB

US2825591033

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
8.51 USD -0.23% Intraday chart for 89bio, Inc. -4.60% -23.81%
Apr. 17 89bio, Inc. Appoints Martin Babler to Its Board of Directors CI
Apr. 03 89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
GL
89bio, Inc. Appoints Martin Babler to Its Board of Directors
CI
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing
MT
Sector Update: Health Care Stocks Gain Wednesday Afternoon
MT
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status
MT
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
GL
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
AQ
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis
CI
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
GL
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
AQ
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis
CI
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
North American Morning Briefing : Stock Futures -2-
DJ
Evercore ISI Adjusts 89bio Price Target to $37 From $29, Maintains Outperform Rating
MT
89bio to Participate in the Leerink Partners Global Biopharma Conference
GL
Thinking about buying stock in Aadi Bioscience, Bitdeer Technologies, Aquestive Therapeutics, 89bio, or Energem?
PR
Top Premarket Gainers
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ETNB Stock
  4. News 89bio, Inc.